High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival

· 2021-11-17

Abstract

Background:

There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects.

Methods:

This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data.

Results:

There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03–1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11–1.54).

Conclusions:

A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival.

Impact:

Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer.

Funding
Epidemiology of Ovarian Cancer:New HypothesesDNA POLYMORPHISMS IN OVARIAN CANCER--CASE CONTROL STUDYRISK FACTOR ANALYSIS OF BRCA1 AND BRCA2 CARRIERSDana-Farber/Harvard Cancer Center Ovarian Cancer SPOREOVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERSPathologyRelating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and RiskPhytoestrogens, alcohol, and endometrial cancer riskRegulatory T Cell Function in Ovarian CancerSURVEILLANCE EPIDEMIOLOGY & END RESULTS PROGRAMProject 1University of Michigan Rogel Cancer Center Support Grant 2023-2028General Clinical Research CenterCancer Center AdministrationInflammation and Ovarian CancerThe Progesterone Receptor Gene and Ovarian Cancer RiskCollaborative Genetic Study of Ovarian Cancer RiskObesity in ovarian cancer prognosisHereditary Breast Cancer: Genetic and Molecular StudiesUniversity of Michigan Training Program in Genomic ScienceCASE CONTROL STUDY OF OVARIAN CANCER HORMONAL ETIOLOGYCancer Research Training and Education CoordinationMedical Research Council Grant MR_UU-12023ESTROGEN, DIET, GENETICS AND ENDOMETRIAL CANCEROvarian Cancer and Gonadotropin SignalingCancer Research UK Grant 15601Genes, Hormones & Environment in an Ovarian Cancer ModelGenetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyCancer Risk Assessment, Early Detection, and Interception Research ProgramThe Molecular Epidemiology Of Ovarian CancerMichigan Center on Lifestage Environmental Exposures and Disease (M-LEEaD)Cancer Research UK Grant 22905Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI)Hormone Therapy and Risk of Ovarian CancerSURVEILLANCE EPIDEMIOLOGY AND END RESULTSSteroid Hormone Genes and Ovarian Cancer RiskProject 2: Next Generation TOP1 Inhibition for the Treatment of Ovarian CancerMedical Research and Materiel Command Grant DAMD17-01-1-0729National Health & Medical Research Council of Australia Grant 199600National Health & Medical Research Council of Australia Grant 400413National Health & Medical Research Council of Australia Grant 400281Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia Grant 191Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia Grant 211Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia Grant 182National Health and Medical Research Council of Australia Grant APP1117044National Health and Medical Research Council of Australia Grant APP1161198National Health and Medical Research Council of Australia Grant APP1092856National Health and Medical Research Council of Australia Grant APP1173346RISK FACTOR ANALYSIS OF BRCA1 AND BRCA2 CARRIERSCASE CONTROL STUDY OF OVARIAN CANCER HORMONAL ETIOLOGYDNA POLYMORPHISMS IN OVARIAN CANCER--CASE CONTROL STUDYSteroid Hormone Genes and Ovarian Cancer RiskNational Institutes of Health (NIH) Grant R01-CA87538U.S. NIH Grant R01-CA58598In vitro and In Vivo screening of chemopreventive agentsCancer Genetic Network (CGN)University of Pittsburgh School of Medicine Dean's Faculty Advancement Award FundingUS Department of Defense Grant DAMD17-02-1-0669OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERSProject 1Regulatory T Cell Function in Ovarian CancerNCI Grant R01-CA95023NCI Grant MO1-RR000056Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyNational Institutes of Health (NIH) Grant P30-CA15083Project 2: Next Generation TOP1 Inhibition for the Treatment of Ovarian CancerNIH Grant R01-CA76016National Institutes of Health Grant DAMD17-02-1-0666NIH Grant R01-CA54419Dana-Farber/Harvard Cancer Center Ovarian Cancer SPOREU.S. Department of Defense (United States Department of Defense) Grant W81XWH-10-1-02802National Cancer Institute Grant NIH-K07 CA095666National Cancer Institute Grant R01-CA83918National Cancer Institute Grant NIH-K22-CA138563Cancer Center AdministrationCancer Institute of New Jersey FundingHereditary Breast Cancer: Genetic and Molecular StudiesLon V Smith Foundation Grant LVS-39420NIH Grant P01CA17054NIH Grant N01PC67010SURVEILLANCE EPIDEMIOLOGY AND END RESULTSCalifornia Cancer Research Program Grant 00-01389V-20170NIH FundingPathology

NCI NIH HHS

R01 CA087538

NCI NIH HHS

R01 CA080742

NCI NIH HHS

R01 CA063678

NCI NIH HHS

P50 CA105009

NCI NIH HHS

K07 CA080668

NCI NIH HHS

P30 CA008748

NCI NIH HHS

R01 CA248288

NCI NIH HHS

R01 CA126841

NCI NIH HHS

N01 PC067010

NCI NIH HHS

P50 CA159981

NCI NIH HHS

P30 CA046592

NCRR NIH HHS

M01 RR000056

NCI NIH HHS

P30 CA072720

NCI NIH HHS

R01 CA095023

NCI NIH HHS

R03 CA113148

NCI NIH HHS

R01 CA058598

NCI NIH HHS

K22 CA138563

NCI NIH HHS

R01 CA058860

NHGRI NIH HHS

T32 HG000040

NCI NIH HHS

R01 CA074850

NCI NIH HHS

P30 CA014089

NCI NIH HHS

R01 CA083918

NCI NIH HHS

R03 CA115195

NCI NIH HHS

R01 CA054419

NCI NIH HHS

R01 CA122443

NCI NIH HHS

P30 CA015083

NCI NIH HHS

R01 CA076016

NIEHS NIH HHS

P30 ES017885

NCI NIH HHS

U19 CA148112

NCI NIH HHS

P01 CA017054

NCI NIH HHS

N01 CN025403

NCI NIH HHS

R01 CA112523

NCI NIH HHS

P50 CA136393

NIH

R01-CA063678

NIH

R01-CA074850

NIH

R01-CA080742

NIH

R01-CA112523

U.S. NIH

N01-CN-55424

U.S. NIH

N01-PC-67001

NCI

K07-CA080668

NCI

P50-CA159981

NCI

R01-CA126841

NIH

R01-CA122443

NIH

P50-CA136393

NIH

P50-CA105009

NCI

P30-CA072720

NIH

R01-CA058860

NIH

N01CN025403

NCI

P30 CA008748